Penumbra, Inc.

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2026-02-06 pm EST			5-day change	1st Jan Change
341.02 ^USD	-0.29%		-4.79%	+9.68%

Feb. 04	Boston Scientific shares slide on cautious 2026 revenue forecast	RE
Jan. 21	When America Starts to Feel Like a Risky Asset

Health Care Down Amid Mixed Earnings -- Health Care Roundup

Published on 01/15/2026 at 05:55 pm EST

Dow Jones

PENUMBRA, INC.

-0.29%

BOSTON SCIENTIFIC CORPORATION

-1.76%

Health-care companies fell as mixed earnings outlook offset deal activity.

Medical-device maker Boston Scientific agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock, as it seeks to add a blood-clot specialist to its portfolio.

The Health and Human Services Department has reversed around $2 billion in grant cuts to substance-abuse and mental-health programs, rescinding termination notices that sent shock waves through organizations that receive funding to help people in recovery and those experiencing mental illness.

President Trump is urging Congress to pass measures lowering prescription drug prices, increasing price transparency and redirecting federal subsidies from insurers to consumers. The proposals are thought to stand little chance in Congress.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-15-26 1754ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	PENUMBRA, INC.	341.02USD	-0.29%	-4.79%	13.36B
	BOSTON SCIENTIFIC CORPORATION	76.27USD	-1.76%	-18.45%	113B

Latest news about Penumbra, Inc.

Feb. 04	Boston Scientific shares slide on cautious 2026 revenue forecast	RE
Jan. 21	When America Starts to Feel Like a Risky Asset
Jan. 20	RBC Downgrades Penumbra to Sector Perform From Outperform, Raises Price Target to $374 From $355	MT
Jan. 20	Cantor Fitzgerald Downgrades Penumbra to Hold From Buy, Adjusts Price Target to $374 From $359	MT
Jan. 20	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
Jan. 20	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
Jan. 16	Needham Downgrades Penumbra to Hold From Buy, Price Target is $388	MT
Jan. 16	Where the Money's Moving
Jan. 16	Truist Securities Downgrades Penumbra to Hold From Buy, Adjusts PT to $374 From $370	MT
Jan. 16	Citigroup Downgrades Penumbra to Neutral From Buy, Adjusts Price Target to $374 From $350	MT
Jan. 16	BTIG Downgrades Penumbra to Neutral From Buy	MT
Jan. 16	Baird Downgrades Penumbra to Neutral From Outperform, Adjusts Price Target to $374 From $345	MT
Jan. 16	Leerink Partners Downgrades Penumbra to Market Perform From Outperform, Adjusts Price Target to $374 From $379	MT
Jan. 16	Analyst recommendations: Hewlett-Packard, Yeti Holdings, Applied Materials, Intel, Netflix…
Jan. 16	RTW Biotech's portfolio firm Penumbra acquired by Boston Scientific	AN
Jan. 15	Health Care Down Amid Mixed Earnings -- Health Care Roundup	DJ
Jan. 15	Wall Street Snaps 2-Day Losing Streak as Semiconductors Shine, Bank Stocks Rise	MT
Jan. 15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jan. 15	Semiconductor, Bank Stocks Help Lift Equity Markets Intraday	MT
Jan. 15	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT
Jan. 15	Sector Update: Health Care	MT
Jan. 15	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
Jan. 15	Sector Update: Health Care	MT
Jan. 15	Strong Chipmaker Earnings Lift Technology Sector, With US Equity Futures Mostly Higher Pre-Bell	MT
Jan. 15	Boston Scientific to Acquire Penumbra in $14.5 Billion Deal	MT

Chart Penumbra, Inc.

Duration

Period

PEN: Dynamic Chart

Company Profile

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Employees

4,500

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 23 - Q4 2025 Earnings Release (Projected)

More about the company